-
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD) A Double-Blinded Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
The purpose of the study is to determine if the invasive disease-free survival (iDFS) with T-DM1 and tucatinib is superior to the iDFS in the ... -
A randomized double-blind placebo-controlled Phase 3 study of Debio 1143 in combo w/ platinum-based chemo & standard fractionation intensitymodulated radiotherapy in patients w/ locally advanced HNSCC suitable for definitive chemoradiotherapy
The purpose of the study is to compare the efficacy and safety of Debio 1143 versus matched placebo, when administered in combination with platinum-based chemotherapy ... -
A Phase 3 Multi-center Randomized Double-blinded Study of MK-7684 with Pembrolizumab as a Co-formulation (MK-7684A) Versus Pembrolizumab Monotherapy as a First Line Treatment for Participants with PD-L1 Positive (TPS>=1%) Metastatic Non-Small Cell Lung Cancer
The purpose of the study is to determine and compare MK-7684A to pembrolizumab alone for participants with PD-L1 Positive (TPS>=1%) Metastatic Non-Small Cell Lung ... -
A Phase 3 Randomized Multicenter Double-Blind Placebo-Controlled Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
The purpose of the study is to evaluate the efficacy of birtamimab plus standard of care compared to placebo plus standard of care in Mayo ... -
A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TAFASITAMAB PLUS LENALIDOMIDE IN ADDITION TO RITUXIMAB VERSUS LENALIDOMIDE IN ADDITION TO RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) GRADE 1-3A OR R/R MARGINAL ZONE LYMPHOMA (MZL)
The purpose of the study is to determine and investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with ... -
A Phase 3 Randomized Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
The purpose of the study is to compare the effectiveness, safety, and toxicity of two treatments: relatlimab and nivolumab vs nivolumab monotherapy in participants with ... -
NRG-BR007: A PHASE III CLINICAL TRIAL EVALUATING DE-ESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I HORMONE SENSITIVE HER2-NEGATIVE ONCOTYPE RECURRENCE SCORE = 18 BREAST CANCER
The purpose of the study is to determine and examine whether breast conservation surgery and endocrine therapy results in a non-inferior rate of ipsilateral-breast tumor ...
-
AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs.Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
The purpose of the study is to minimize toxicity by reducing therapy while maintaining current survival rates in the treatment of pediatric, adolescent and young ... -
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk clinically localised prostate cancer
The purpose of the study is to determine the effectiveness of darolutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinising hormone releasing ... -
ACNS1931: A Phase 3 Study of Selumetinib (NSC# 748727 IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1 non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
The purpose of the study is to determine and investigate the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine ...